← Back to all trials
Active Not Recruiting
NCT05791201
A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
Conditions: Type 1 Diabetes
Sex: All
Ages: 18 Years – 65 Years
Healthy volunteers: No
Phase: PHASE1, PHASE2
Enrollment: 7
Sponsor: Vertex Pharmaceuticals Incorporated
Location: UHealth Diabetes Research Institute Miami Florida
Summary
The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).
Eligibility Criteria
Key Inclusion Criteria:
Clinical history of T1D with greater than or equal to (\>=) 5 years duration Participant is on a stable diabetic treatment Consistent use of continuous glucose monitoring (CGM) for at least 4 weeks before Screening and willingness to use CGM for the duration of the study
Key Exclusion Criteria:
Prior islet cell transplant, organ transplant, or cell therapy
Source: ClinicalTrials.gov (NCT05791201). StuddyBuddy aggregates publicly available trial information.
